Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has provided an update.
Orexo AB has announced the issuance and immediate repurchase of 2,446,000 class C shares to support its long-term incentive programs from 2023 to 2025. These shares, initially subscribed by Danske Bank, will be converted into ordinary shares for distribution to program participants, ensuring the company’s commitment to its incentive schemes.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies to address significant medical needs. The company offers innovative treatment solutions for opioid use disorder in the US and develops products for other therapeutic areas globally with leading partners. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US, with 2024 net sales of SEK 590 million and 110 employees.
Average Trading Volume: 19,279
Current Market Cap: SEK685.9M
See more insights into ORX stock on TipRanks’ Stock Analysis page.